Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dolby Laboratories, Inc. (DLB) vs Mesoblast Limited (MESO) Price & Performance

Dolby Laboratories, Inc.Trade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Dolby Laboratories, Inc. vs Mesoblast Limited — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.82B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Dolby Laboratories, Inc. is far larger — about 2.7× Mesoblast Limited's market cap, and Dolby Laboratories, Inc. pays a 2.32% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

DLBMESO
Market Cap
$5.82B$2.16B
Sector
IndustrialsTechnology
52-Week High
$75.62$20.96
52-Week Low
$48.51$12.88
Enterprise Value
$5.19B$2.17B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dolby Laboratories, Inc.

Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.

DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO